Can a vaccine plus immune booster tackle resistant prostate cancer?

NCT ID NCT07756593

First seen Aug 10, 2026 · Last updated Aug 11, 2026 · Updated 1 time

Summary

This early-phase trial is testing whether combining two immune-based treatments—Sipuleucel-T, a vaccine made from a patient's own immune cells, and N-803, a drug that boosts immune activity—is safe and tolerable for men with metastatic prostate cancer that has stopped responding to hormone therapy. The study enrolls 30 participants and aims to find the best dose of N-803 to use with the standard Sipuleucel-T regimen. Researchers will monitor side effects and also look at whether the combination affects PSA levels, a marker of prostate cancer activity.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Sipuleucel-T (a cellular vaccine) combined with N-803 (an immune-boosting biologic)
What this could lead to
If safe and effective, this combination could offer a new treatment option for metastatic prostate cancer that has stopped responding to hormone therapy.
What could go wrong
This is an early-phase trial with only 30 participants, so results may not apply broadly. The combination could cause significant side effects, and it's unclear if it will improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for METASTATIC ANDROGEN PATHWAY MODULATION RESISTANT PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Washington University School of Medicine

    St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.